Loading...
Docoh

Gamida Cell (GMDA)

Utility
Method of Homing and Retention of Gammadelta T Cells, Optionally with Natural Killer Cells, for Generating Cell Compositions for Use In Therapy
12 May 22
Methods of ex-vivo culture of gammadelta T-cells and gammadelta T-cell enriched cell populations are provided and, more particularly, methods for enhancing functionality of gammadelta T-cell populations by treating the cells with a nicotinamide in combination with cytokines enhancing gammadelta T-cell homing and/or retention potential.
Tony PELED
Filed: 24 Feb 20
Utility
Expansion and Use of Expanded NK Cell Fractions
19 Aug 20
Methods of expanding a natural killer (NK) cell fraction for transplantation into a subject are provided, and particularly, methods for providing transplantable NK cell fractions and protocols for their use, which can be employed for applications in cell transplants and infusions for treatment of cancer and other disease.
Tony PELED
Filed: 26 Sep 18
Utility
Selection and Use of Umbilical Cord Cell Fractions Suitable for Transplantation
3 Jun 20
Methods of selecting umbilical cord blood units for ex-vivo expansion, separation of CD133+/CD34+ positive and uncultured CD133+/CD34+ negative fractions, methods for expanding the selected CD133+/CD34+ fraction, selection of expanded populations of CD133+/CD34+ cord blood cells for transplantation to subjects in need thereof and the therapeutic use of suitable selected, ex-vivo expanded CD133+/CD34+ and unselected CD133/CD34 negative cord blood fractions for transplantation in the clinical setting, for treatment of hematological malignancies are provided.
Tony PELED, Einat Galamidi COHEN, David SNYDER
Filed: 15 May 17
Utility
Selection and Use of Umbilical Cord Cell Fractions Suitable for Transplantation
6 May 20
Methods of selecting umbilical cord blood units for ex-vivo expansion, separation of CD133+/CD34+ positive and uncultured CD133+/CD34+ negative fractions, methods for expanding the selected CD133+/CD34+ fraction, selection of expanded populations of CD133+/CD34+ cord blood cells for transplantation to subjects in need thereof and the therapeutic use of suitable selected, ex-vivo expanded CD 133+/CD34+ and unselected CD133/CD34 negative cord blood fractions for transplantation in the clinical setting, for treatment of hematological malignancies are provided.
Tony PELED, Dorit HARATI, Efrat LANDAU
Filed: 15 May 18
  • 1
Patents are sorted by USPTO publication date, most recent first